Follow up from FredHere is for your info. English is below with the help of Google translate.
Have a great weekend,
Chris1056
Bonjour Fred,
La raison de ce courriel est pour savoir qu'est-ce qui se passe avec l'enfant en Allemagne et la dame de 36 ans qui ont eu un traitement trs favorable au Plasminogne l'automne dernier et qui ont fait l'objet de deux "News Release", 4 nov. et 7 dc.?
Leur condition continue-t-elle de s'amliorer?
Sont-ils encore traiter au Plasminogne?
Si oui, quelle frquence et quelle quantit est utilise?
Merci et continuez votre bon travail, salutations,
Chris
Salut Chris,
Je pense que le jeune patient en Allemagne est toujours sous traitement. Malheureusement, il a manqu d’oxygne avant le dbut des traitements avec le plasminogne et je pense qu’il devra vivre avec certaines complications mais notre mdicaments lui a sauv la vie. Il reste voir pour le futur.
Quant la patiente de 36 ans de Californie, elle faisait partie de la phase I de l’tude clinique. Elle ne reoit plus le mdicament en ce moment et les lsions reviennent. Ce qui prouve que notre mdicament fait exactement ce qu’il est suppos faire. Une seule infusion et les lsions disparaissent. Elle arrte et les lsions reviennent. Elle s’est dj porte volontaire pour la phase II/III. Tout se droule comme prvu.
Nous donnerons plus de prcisions lorsque la phase II/III sera complte vers le milieu de l’anne.
Salutations,
Frederic
Frdric Dumais, B. Comm., LLB.
Directeur principal, Communications et relations avec les investisseurs
Senior Director, Communications and Investor Relations
ProMetic Sciences de la Vie inc.
ProMetic Life Sciences Inc.
440 boul. Armand-Frappier, bureau (suite) 300
Laval, Qubec, Canada
H7V 4B4
Tel. : 450-781-0115
Fax : 450-781-4477
Mobile : 514-261-4735
f.dumais@prometic.com www.prometic.com Hello Fred,
The reason for this email is to know what is happening with the child in Germany and the lady of 36 years old who have had a very favorable treatment with Plasminogen last fall and were mentioned in two "News Release", November 4 and December 7?
Does their condition continue to improve?
Are they still treated with Plasminogen?
If so, how often and how much is being used?
Thank you and keep up the good work, greetings,
Chris
From Fred. Hi Chris,
I think the young patient in Germany is still under treatment. Unfortunately, he lacked of oxygen before the start of the treatment with Plasminogen and I think he will have to live with some complications but our drug saved his life. It remains to see in the future.
As for the 36 years old woman in California, she was part of the Phase I clinical study. She does not receive the drug at this time and lesions are back. This proves that our drug does exactly what it is supposed to do. One infusion and the lesions disappear. She stops and lesions are back. She has already volunteered for Phase II / III. Everything is going as planned.
We will give more details when the phase II / III will be completed by the middle of the year.
Greetings
Frederic